Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Anti-obesity drug discovery: advances and challengesNature reviews. Drug discovery, 2022-03, Vol.21 (3), p.201-223 [Peer Reviewed Journal]2021. Springer Nature Limited. ;Springer Nature Limited 2021 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/s41573-021-00337-8 ;PMID: 34815532Full text available |
|
2 |
Material Type: Article
|
Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesThe New England journal of medicine, 2016-11, Vol.375 (18), p.1799 [Peer Reviewed Journal]EISSN: 1533-4406 ;PMID: 27806237Full text available |
|
3 |
Material Type: Article
|
Type 2 diabetesThe Lancet (British edition), 2022-11, Vol.400 (10365), p.1803-1820 [Peer Reviewed Journal]2022 Elsevier Ltd ;Copyright © 2022 Elsevier Ltd. All rights reserved. ;2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)01655-5 ;PMID: 36332637Full text available |
|
4 |
Material Type: Article
|
Advances in oral peptide therapeuticsNature reviews. Drug discovery, 2020-04, Vol.19 (4), p.277-289 [Peer Reviewed Journal]COPYRIGHT 2020 Nature Publishing Group ;COPYRIGHT 2020 Nature Publishing Group ;Springer Nature Limited 2019. ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/s41573-019-0053-0 ;PMID: 31848464Full text available |
|
5 |
Material Type: Article
|
Cellular and Molecular Mechanisms of Metformin ActionEndocrine reviews, 2021-02, Vol.42 (1), p.77-96 [Peer Reviewed Journal]The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. 2020 ;Copyright © Oxford University Press 2015 ;The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. ;COPYRIGHT 2021 Oxford University Press ;ISSN: 0163-769X ;EISSN: 1945-7189 ;DOI: 10.1210/endrev/bnaa023 ;PMID: 32897388Full text available |
|
6 |
Material Type: Article
|
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysisEuropean heart journal, 2022-02, Vol.43 (6), p.474-484 [Peer Reviewed Journal]The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. 2021 ;The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. ;The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. 2021 ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehab777 ;PMID: 35023547Full text available |
|
7 |
Material Type: Article
|
Forget polypharmacy for type 2 diabetes! Weight management is a better investmentNephrology, dialysis, transplantation, 2022-04, Vol.37 (5), p.844-846 [Peer Reviewed Journal]ISSN: 0931-0509 ;EISSN: 1460-2385 ;DOI: 10.1093/ndt/gfaa250 ;PMID: 33263751Full text available |
|
8 |
Material Type: Article
|
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 TrialCirculation (New York, N.Y.), 2020-04, Vol.141 (15), p.1227-1234 [Peer Reviewed Journal]2020 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.119.044183 ;PMID: 31983236Full text available |
|
9 |
Material Type: Article
|
Cardiovascular disease in diabetes, beyond glucoseCell metabolism, 2021-08, Vol.33 (8), p.1519-1545 [Peer Reviewed Journal]2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;ISSN: 1550-4131 ;EISSN: 1932-7420 ;DOI: 10.1016/j.cmet.2021.07.001 ;PMID: 34289375Full text available |
|
10 |
Material Type: Article
|
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational StudyDiabetes care, 2020-12, Vol.43 (12), p.2999-3006 [Peer Reviewed Journal]2020 by the American Diabetes Association. ;Copyright American Diabetes Association Dec 1, 2020 ;2020 by the American Diabetes Association 2020 ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dc20-1521 ;PMID: 32994187Full text available |
|
11 |
Material Type: Article
|
The mechanisms of action of metforminDiabetologia, 2017-09, Vol.60 (9), p.1577-1585 [Peer Reviewed Journal]The Author(s) 2017 ;Diabetologia is a copyright of Springer, 2017. ;ISSN: 0012-186X ;EISSN: 1432-0428 ;DOI: 10.1007/s00125-017-4342-z ;PMID: 28776086Full text available |
|
12 |
Material Type: Article
|
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England journal of medicine, 2016-03, Vol.374 (11), p.1092-1094 [Peer Reviewed Journal]Copyright © 2016 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMc1600827 ;PMID: 26981940Full text available |
|
13 |
Material Type: Article
|
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2022-12, Vol.65 (12), p.1925-1966 [Peer Reviewed Journal]American Diabetes Association and the European Association for the Study of Diabetes 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;2022. American Diabetes Association and the European Association for the Study of Diabetes. ;American Diabetes Association and the European Association for the Study of Diabetes 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;ISSN: 0012-186X ;EISSN: 1432-0428 ;DOI: 10.1007/s00125-022-05787-2 ;PMID: 36151309Full text available |
|
14 |
Material Type: Article
|
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialNature Medicine, 2022-03, Vol.28 (3), p.568-574 [Peer Reviewed Journal]2022. The Author(s). ;The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Attribution ;The Author(s) 2022 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;EISSN: 1744-7933 ;DOI: 10.1038/s41591-021-01659-1 ;PMID: 35228754Full text available |
|
15 |
Material Type: Article
|
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemiaEuropean heart journal, 2020-10, Vol.41 (40), p.3936-3945 [Peer Reviewed Journal]The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. 2020 ;The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehaa689 ;PMID: 32860031Full text available |
|
16 |
Material Type: Article
|
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection FractionThe New England journal of medicine, 2022-09, Vol.387 (12), p.1089-1098 [Peer Reviewed Journal]Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;COPYRIGHT 2022 Massachusetts Medical Society ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2206286 ;PMID: 36027570Full text available |
|
17 |
Material Type: Article
|
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trialsThe Lancet (British edition), 2022-09, Vol.400 (10354), p.757-767 [Peer Reviewed Journal]Copyright © 2022 Published by Elsevier Ltd. All rights reserved. Published by Elsevier Ltd.. All rights reserved. ;2022. Published by Elsevier Ltd. All rights reserved ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)01429-5 ;PMID: 36041474Full text available |
|
18 |
Material Type: Article
|
Empagliflozin in Patients with Chronic Kidney DiseaseThe New England journal of medicine, 2023-01, Vol.388 (2), p.117-127 [Peer Reviewed Journal]Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;COPYRIGHT 2023 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2204233 ;PMID: 36331190Full text available |
|
19 |
Material Type: Article
|
Dapagliflozin in Patients with Chronic Kidney DiseaseThe New England journal of medicine, 2020-10, Vol.383 (15), p.1436-1446 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2024816 ;PMID: 32970396Full text available |
|
20 |
Material Type: Article
|
The health effects of vitamin D supplementation: evidence from human studiesNature reviews. Endocrinology, 2022-02, Vol.18 (2), p.96-110 [Peer Reviewed Journal]2021. Springer Nature Limited. ;Springer Nature Limited 2021. ;Springer Nature Limited 2021 ;ISSN: 1759-5029 ;EISSN: 1759-5037 ;DOI: 10.1038/s41574-021-00593-z ;PMID: 34815552Full text available |